HLB's rivoceranib plus camrelizumab extends survival in poor prognosis hepatocellular carcinoma patients

HLB's rivoceranib plus camrelizumab extends survival in poor prognosis hepatocellular carcinoma patients. (Photo courtesy of IT Times)

 

On October 13, 2025, HLB announced that its U.S. subsidiary, Elevar Therapeutics, released a post-hoc exploratory analysis of the global Phase 3 CARES-310 trial, to be presented at ESMO 2025 in Berlin on October 17. The abstract showed that the combination of rivoceranib and camrelizumab significantly improved overall survival (mOS) and progression-free survival (mPFS) in patients with poor-prognosis hepatocellular carcinoma, including those with extrahepatic metastasis or macrovascular invasion. Patients with extrahepatic metastasis achieved a median OS of 23.5 months versus 13.0 months with sorafenib, and median PFS improved to 5.6 months from 3.6 months. Among those with macrovascular invasion, mPFS increased to 5.5 months versus 3.0 months. Adverse events were manageable, with liver enzyme elevation most common in the combination group. HLB emphasized that these results confirm the therapy’s consistent efficacy across disease stages and support its potential as a first-line treatment for advanced liver cancer.

IT Times: https://www.ittimes.com/news/articleView.html?idxno=81006

HLB's rivoceranib plus camrelizumab extends survival in poor prognosis hepatocellular carcinoma patients - IT타임스